Radiotherapy of inoperable lung cancer.
Explore the source record for details and available documents.
Carcinoma, Squamous Cell↗
Biomedical subjects
J L Boublil
Publications and source records attributed to J L Boublil.
[Polyamines: clinical, diagnostic and prognostic value].
Explore the source record for details and available documents.
Body Fluids↗
An improved method for routine analysis of polyamines in biological fluids with a conventional amino acid analyzer.
An accurate and precise mechanized ion-exchange chromatographic method for the estimation of polyamines in biological fluids is described. The method includes the recent improvements developed for ion-exchange analysis of polyamines: the use of sulfonated polystyrene cation-exchange resin with a bead diameter of less than 10 micrometers and a continuous fluorescent detection with o-phthalaldehyde. Four different procedures for the removal of protein before analysis of polyamines in plasma have been compared. Linearity of the fluorescence detection, reproducibility (intra, inter assay) and precision of the retention times are reported. Furthermore, the method is characterised by the simplicity of the sample preparation, a clear and rapid elution programme and especially by its routine applicability, as shown during the last six months in the Centre Antoine-Lacassagne.
Amino Acids↗
[Polyamines and malignant diseases (author's transl)].
The aliphatic polyamines (putrescine, spermidine, spermine) are associated with the phenomena of normal and neoplastic cellular growth. Two third of cancers generally show elevated urinary excretion of polyamines. The urinary levels of polyamines are significantly higher in cancer in evolution than in cancer in remission. The variable association of polyamines with different localisations is reviewed. The potential interest of polyamines analysis in the diagnosis and prognosis of cancer is discussed. The more exciting application of this test remains in the possibility of a short term appreciation of the oncostatic treatment efficiency.
Cell Division↗
[Exploration and surveillance of the retroperitoneal space by lymphography and ultrasonography in patients with non-Hodgkin's lymphomas (author's transl)].
The authors propose to conduct, in a systematic manner, lymphography and ultrasonography examinations before treatment of 75 cases of non-Hodgkin's lymphoma. The latter investigation enables examination of the upper part of the retroperitoneal space, and the detection of coeliomesenteric adenopathies, or possible lesions in the liver, spleen, and kidneys. The surveillance of most patients during treatment is possible with ultrasonography, if marked lipiodol resorption has occurred. Though this procedure is easy to conduct in all radiological departments, it does not have the same sensitivity as lymphography associated with computed tomography.
Humans↗
The clinical value of urinary polyamine analyses in cancer patients.
The polyamines, putrescine (P) and spermidine (S), have been measured in 185 cancer patients. Patients in remission exhibited significantly different levels from those with active disease. In a dynamic patient study, followed over a period of 5-6 months, the urinary polyamine levels correlated closely with the clinical status. Furthermore, polyamines have been measured 24 h before beginning chemotherapy (P1, S1) and 48 h after its onset (P2, S2). The value of the ratio, (S2/P2)/(S1/P1), was found to correlate with the type of response to chemotherapy.
Adolescent↗
Systemic blood levels after intra-arterial administration of microencapsulated mitomycin C in cancer patients.
Systemic delivery of mitomycin C (MMC) was studied in 6 patients administered microencapsulated MMC (MMC-mc) by an intra-arterial route (IA): 3 IA liver infusions, 3 IA pelvic infusions. Pharmacokinetic data revealed a lower blood MMC availability (peak plasma levels, AUC 0-4 hours) for the pelvis than for the liver; this was attributed to differences in the blood flow infusion rates at these two sites of administration. Direct comparison of systemic MMC exposure was possible for one patient, who received both IA liver MMC (10 mg in standard form, which served as the control) and IA liver MMC-mc (20 mg the day after). The 65% reduction in MMC-mc bioavailability observed for this patient indicates a quantitative local improvement in exposure to the drug and correlates well with the low incidence of systemic side effects noted in preliminary clinical studies.
Aged↗